The CHARISMA study, for example, suggested that
long-
term dual antiplatelet therapy in patients with vascular disease reduces death, MI, and stroke, but that benefit may not be specific to DES....The issue of restenosis with DES is the reference in the post, and there is evidence dual therapy helps reduce restenosis with DES...mechanism is not known, but the mechanism of action, etiology, differs between the two anti-platelet medications.